Yet Another bispecific, humanized IgG1 antibody that's less than investigation is zenocutuzumab (MCLA-128), which acts through two unbiased mechanisms of motion: inhibition of HER2–HER3 signalling and elimination of tumour cells via ADCC. MCLA-128 capabilities by using a ‘dock and block’ mechanism whereby one arm with the antibody binds HER2 area https://www.directivepublications.org/journal-of-clinical-breast-cancer/